SAFETY AND EARLY EFFICACY SIGNALS OF THE FIRST-IN-CLASS DOPAMINE Β-HYDROXYLASE INHIBITOR APL-1401 IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS: PRIMARY RESULTS FROM A 4-WEEK RANDOMIZED PHASE 1B TRIAL

nepicastat (APL-1401) - Asieris

Xiaowei Liu; Gary Reiss; Lius Lopez; Changqing Zheng; Xiaolan Zhang; Ping An; Yingjian Zhang; Haipeng Yuan; Yu Cao; Qun Qin; Xiaoliang Yuan

Jan 27, 2026